PAVmed Digital Health Subsidiary Veris Health Launches Veris Cancer Care Platform
15 12월 2022 - 10:25PM
Business Wire
Executes first commercial contract with leading
New Jersey oncology practice
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), a
diversified commercial-stage medical technology company, operating
in the medical device, diagnostics, and digital health sectors,
today announced that its majority-owned digital health subsidiary
Veris Health Inc. (“Veris”), has commercially launched its Veris
Cancer Care Platform™ (“Veris CCP”). Veris executed its first
commercial contract with New Jersey Cancer Care, PA (“NJCC”), a
leading oncology practice and member of the prestigious Quality
Cancer Care Alliance.
“Veris’ first commercial launch is a testament to our team and
partners’ hard work over the past eighteen months,” said Lishan
Aklog, M.D., PAVmed’s Chairman &
Chief Executive Officer and Veris’ Executive Chairman. “We are
excited to offer oncology practices and their patients a
state-of-the-art cancer-focused digital health platform designed to
enhance care and improve outcomes through remote patient monitoring
(RPM). Our software-as-a-service recurring-revenue business model
leverages well-established RPM codes and provides attractive
margins to Veris and its clients. We look forward to further
enhancing the power of the platform next year, with the anticipated
launch of our implantable physiological monitor designed to be
implanted in conjunction with a vascular access port for
chemotherapy.”
“At New Jersey Cancer Care we take pride in staying on the
cutting edge of science and technology and delivering unsurpassed
personal attention to our patients,” said NJCC’s Executive
Director, Denise Johnstone. “We are excited to implement the Veris
Cancer Care Platform. Its groundbreaking remote patient monitoring
tools will help us enhance the care of our patients while
strengthening our practice’s economics.”
Veris CCP is a digital cancer care platform with physiologic
data collection, symptom reporting and telehealth functions,
designed to improve personalized cancer care through remote patient
monitoring. Cancer patients enrolled in the Veris CCP program
receive a VerisBox™ with Veris-branded Bluetooth enabled connected
health care devices. The devices transmit clinical data to the
cancer care team through the Veris CCP patient smartphone app and
the cloud-based Veris CCP clinician portal. The platform will allow
the cancer care team to detect early signs of common cancer-related
complications, provide longitudinal trends of physiologic and
clinical data, and offer data-driven risk management tools for
precision oncology. The practice uses RPM codes to bill for review
and interpretation of clinical data.
About PAVmed and Veris
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics, and digital
health sectors. Its majority-owned subsidiary, Veris Health Inc.,
is a digital health company focused on enhanced personalized cancer
care through remote patient monitoring using implantable biologic
sensors with wireless communication along with a custom suite of
connected external devices. PAVmed’s other majority-owned
subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), is a
commercial-stage cancer prevention medical diagnostics company
which markets the EsoGuard® Esophageal DNA Test and EsoCheck®
Esophageal Cell Collection Device—the first and only commercial
tools for widespread early detection of esophageal precancer to
prevent esophageal cancer deaths. PAVmed’s product pipeline also
includes the CarpX® Minimally Invasive Device for Carpal Tunnel
Syndrome, EsoCure™ Esophageal Ablation Device with Caldus™
Technology, and PortIO™ Implantable Intraosseous Vascular Access
Device, as well as other earlier stage technologies. For more
information on PAVmed, please visit PAVmed.com and follow PAVmed on
Twitter, LinkedIn, and YouTube. For more information on Veris,
please visit VerisHealth.com and follow Veris on Twitter and
LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of PAVmed’s management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of PAVmed’s common stock; general economic and market
conditions; the uncertainties inherent in research and development,
including the cost and time required to advance PAVmed’s products
to regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from PAVmed’s clinical and
preclinical studies; whether and when PAVmed’s products are cleared
by regulatory authorities; market acceptance of PAVmed’s products
once cleared and commercialized; PAVmed’s ability to raise
additional funding as needed; and other competitive developments.
In addition, PAVmed has been monitoring the COVID-19 pandemic and
the pandemic’s impact on PAVmed’s businesses. PAVmed expects the
significance of the COVID-19 pandemic, including the extent of its
effect on its financial and operational results, to be dictated by,
among other things, the success of efforts to contain the pandemic
and the impact of such efforts on PAVmed’s businesses. These
factors are difficult or impossible to predict accurately and many
of them are beyond PAVmed’s control. In addition, new risks and
uncertainties may arise from time to time and are difficult to
predict. For a further list and description of these and other
important risks and uncertainties that may affect PAVmed’s future
operations, see Part I, Item 1A, “Risk Factors,” in PAVmed’s most
recent Annual Report on Form 10-K filed with the Securities and
Exchange Commission, as the same may be updated in Part II, Item
1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by
PAVmed after its most recent Annual Report. PAVmed disclaims any
intention or obligation to publicly update or revise any
forward-looking statement to reflect any change in its expectations
or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that
actual results will differ from those contained in the
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221215005553/en/
Investors and Media Adrian K.
Miller PAVmed Inc. AKM@PAVmed.com
PAVmed (NASDAQ:PAVMZ)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
PAVmed (NASDAQ:PAVMZ)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024